iSpecimen Signs $4.5M M&A Deal with Foldlab AI Ltd.
iSpecimen Inc. completed the acquisition of AI software assets from Foldlab AI Ltd. for an aggregate purchase price of $4.5 million, consisting of $750,000 in cash, $1.25 million in milestone payments, and $2.5 million in common stock. The acquired assets include a Disease-Associated Protein Discovery AI Agent and a Disease Trend Prediction and Monitoring AI Model, marking the company's entry into AI-powered drug discovery.
- Value
- $4.5M
- Counterparty
- Foldlab AI Ltd.